Anti cd14 pb

Manufactured by BioLegend

Sourced in United States

Anti-CD14 PB is a fluorescently-labeled antibody that specifically binds to the CD14 cell surface receptor. CD14 is a glycosylphosphatidylinositol (GPI)-anchored protein expressed primarily on monocytes and macrophages and plays a role in the innate immune response.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd86 pe, by BioLegend (1 mentions) Anti cd83 fitc, by BioLegend (1 mentions) Legendplex human anti virus response panel 13 plex, by BioLegend (1 mentions) Anti mhc 2 fitc, by BioLegend (1 mentions) Anti cd34 apc, by BD (1 mentions) Anti cd45 apc, by BD (1 mentions) Anti cd56 percp cy5, by BD (1 mentions) Anti cd38 v450, by BD (1 mentions) Anti cd14 pecy7, by BioLegend (1 mentions) Anti cd16 fitc, by BD (1 mentions)

Spelling variants of this product

CD14-PB (2 citations)

2 protocols using anti cd14 pb

Antiviral Cytokine Analysis of MoDCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

At 24 h post-stimulation, supernatant and MoDCs were collected for analysis. Antiviral cytokines levels in the supernatant were measured using cytometric bead array [LEGENDplex™ Human Anti-Virus Response Panel (13-plex), BioLegend, San Diego, CA, USA].
Phenotypic maturation of MoDCs was analyzed by flow cytometry using anti-CD14 PB, anti-CD86 PE, anti-MHC II FITC, anti-CD83 FITC, and anti-CD155 APC (Biolegend, San Diego, CA, USA).

Luk A.D., Ni K., Wu Y., Lam K.T., Chan K.W., Lee P.P., Tu W., Mao H, & Lau Y.L. (2018). Type I and III Interferon Productions Are Impaired in X-Linked Agammaglobulinemia Patients Toward Poliovirus but Not Influenza Virus. Frontiers in Immunology, 9, 1826.

+ Open protocol

+ Expand

Immunophenotyping of Myeloid Malignancies

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 5 £ 10 5 PBMCs were initially labeled with either anti-MUC1 SEA antibody DMB5F3 (murine ascites diluted to 1/200) or anti-MUC1 tandem repeat antibody HMFG1 diluted to 1/200 in PBS, followed by phycoerythrin (PE)-conjugated goat F(ab')2 anti-mouse IgG (Beckman Coulter Immunotech, Marseille, France). To characterize AML cells, anti-CD14 PECy7 (BioLegend, San Diego, CA), anti-CD34 APC, anti-CD38 V450, and anti-CD34 APC (all three from BD Biosciences, Le Pont de Claix, France) were reacted with cells. To specifically identify CMML cells, a battery of antibodies to CMML-associated antigens was used, including anti-CD16 FITC, anti-CD56 PercpCy5.5, and anti-CD45 APC (all three from BD Biosciences) and anti-CD14 PB (BioLegend). To identify AML presumed stem cells, a cocktail of lineage-specific FITC-labeled antibodies (anti-CD3, CD14, CD16, CD19, CD20, and CD56) as well as anti-CD34 and anti-CD38 (all from BD Biosciences) was used.

Guillaume T., Dehame V., Chevallier P., Peterlin P., Garnier A., Grégoire M., Pichinuk E., Rubinstein D.B, & Wreschner D.H. (2019). Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. Experimental hematology, 70.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!